CPI

Schwab Trading Activity Index™: Score Ascends to Moderate Levels in March

Retrieved on: 
Monday, April 8, 2024
Professional Services, Business, Finance, Fintech, Asset Management, Banking, Consumer, Education, CPI, VIX, Labour, Federal Reserve, Name, STAX, S&P, Activity, Current Population Survey, Fed, PPI, Producer, Multimedia, Treasury, Consumer confidence, CBOE, Financial adviser

The Schwab Trading Activity Index™ (STAX) increased to 51.65 in March, up from its score of 47.65 in February.

Key Points: 
  • The Schwab Trading Activity Index™ (STAX) increased to 51.65 in March, up from its score of 47.65 in February.
  • View the full release here: https://www.businesswire.com/news/home/20240408112995/en/
    Schwab Trading Activity Index March 2024 (Graphic: Charles Schwab)
    The reading for the four-week period ending March 28, 2024 ranks “moderate” compared to historic averages and marks the highest reading since May 2022.
  • “In the face of undeniably mixed macroeconomic data, the markets soared this month, and the STAX score continued its rise in step,” said Joe Mazzola, Director of Trading and Education at Charles Schwab.
  • “Despite the market highs, however, Schwab clients remain in the moderate range of market exposure as measured by the STAX.

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Friday, March 22, 2024
SIV, Clinical trial, Hepatitis, Head, CPI, Serum, Hepatitis B, Partnership, HIV, Oncology, Gilead Sciences, Patient, Lung, Journal, Viral load, Pembrolizumab, HBV, Trial of the century, IND, Infection, Hepatocyte, Arenavirus, Antibody, Vaccination, Intellectual property, FDA, Liver, Animal, Pharmaceutical industry

“It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.

Key Points: 
  • “It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.
  • Data was initially presented in May 2023 and additional patient data was provided in October at the European Society for Medical Oncology Congress 2023.
  • HOOKIPA expects to initiate a Phase 1 clinical study of HB-500 in people with HIV in the second quarter of 2024.
  • In June 2023, the Company completed a $50.0 million public offering of common stock and non-voting convertible preferred stock.

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, Combination, CPI, AML, Caregiver, Bone marrow, Insurance, Patient, Merck, Acute myeloid leukemia, Cancer, Public expenditure, Pembrolizumab, Lung cancer, Trial of the century, Cytokine release syndrome, AACR, Chemokine, Clinical trial, Annual report, Safety, Workforce, Infrared spectroscopy correlation table, NK, VISTA, Pharmaceutical industry

SEATTLE, March 21, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives, announced today financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • In February 2024, the Company announced a significant corporate restructuring to substantially reduce expenses and preserve cash.
  • We truly appreciate the efforts of the healthcare professionals, the patients and their caregivers, and the Kineta employees involved in this trial.
  • Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors.
  • Cash position: As of December 31, 2023, cash was $5.8 million, compared to $13.1 million as of December 31, 2022.

Nexus Industrial REIT Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Nexus, CPI, Growth, DRIP, Class, Acquisition, Sale, News, Public expenditure, Park Street, Table, NOI, Bank statement, REIT, Analysis, Real estate

TORONTO, March 13, 2024 (GLOBE NEWSWIRE) -- Nexus Industrial REIT (the “REIT”) (TSX: NXR.UN) announced today its results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • See Appendix A of this earnings release for a reconciliation of the non-IFRS financial measures to the primary financial statement measures.
  • Acquisitions completed subsequent to October 1, 2022, generated $4.5 million of incremental NOI in Q4 2023 as compared to Q4 2022.
  • The REIT is focused on delivering total unitholder return through profitable long-term growth, and by pursing its strategy as a Canada-focused pure-play industrial REIT.
  • In the fourth quarter of 2024, the REIT expects to complete the 240,000 sq ft Dennis Rd expansion project in St Thomas, ON.

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

Retrieved on: 
Tuesday, March 12, 2024
Combination, CPI, Immunosuppression, Patient, Tumor microenvironment, Merck, Cancer, Pembrolizumab, Lung cancer, DLT, Merck & Co., Kineta, NK, Pharmaceutical industry

SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as monotherapy and in combination with Merck’s anti-PD therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab. KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.

Key Points: 
  • KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
  • KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
  • We continue to be encouraged by the safety profile of KVA12123, supporting advancement to higher doses,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Tuesday, April 2, 2024
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Shift, Principal, CPI, Drainage, Environment, Refractive surgery, ASCRS, Patient, COE, Acquisition, Faculty, Cataract, MBA, CPC, Society, Safety, Paradigm shift, Pharma, FACS, CPMA, FDA, Annual general meeting, Pharmaceutical industry

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024.

Key Points: 
  • Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024.
  • LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
  • “The recent acquisition of Visant Medical along with Amring Pharmaceuticals becoming Nordic Pharma, Inc., has increased our internal know-how and assets.
  • This is where science and innovation come together, making it the perfect environment to highlight this novel therapy for dry eye.”

CPI Card Group Announces Additional Stock Purchase Agreement with Majority Shareholder Parallel49 Equity ULC

Retrieved on: 
Friday, March 15, 2024
Technology, Personal Finance, Payments, Finance, Banking, Professional Services, Software, Retail, Online Retail, Audit committee, PMTS, Fund, Share repurchase, CPI, LP

The new agreement covers the period April through June and follows an initial agreement that expires on March 31, 2024.

Key Points: 
  • The new agreement covers the period April through June and follows an initial agreement that expires on March 31, 2024.
  • As of December 31, 2023, Parallel49 owned 6.6 million shares of CPI common stock, or approximately 57% of outstanding shares.
  • CPI purchasing shares from Parallel49 at a 3 to 1 ratio to open market purchases maintains or reduces the Parallel49 ownership percentage in CPI and minimizes the share repurchase program’s impact on CPI’s public float.
  • CPI and Parallel49 may enter into similar agreements in the future, consistent with the Company’s share repurchase authorization.

CPI Card Group® Partners With MEA Financial Enterprises LLC to Offer Cardholder Solutions for Digital Wallets

Retrieved on: 
Wednesday, March 13, 2024
Technology, Payments, Finance, Banking, Other Technology, Professional Services, Software, Data Management, Other Professional Services, Rhea, CPI, Software as a service, Digital, Business development, PMTS, MEA, Online shopping

CPI Card Group Inc. (Nasdaq: PMTS) (“CPI” or “the Company”), a payments technology company providing a range of credit, debit, and prepaid card and digital solutions, including Software-as-a-Service (SaaS) instant issuance, today announced a referral relationship with MEA Financial Enterprises LLC (“MEA”), a national leader in the provision of innovative software solutions to the financial services marketplace.

Key Points: 
  • CPI Card Group Inc. (Nasdaq: PMTS) (“CPI” or “the Company”), a payments technology company providing a range of credit, debit, and prepaid card and digital solutions, including Software-as-a-Service (SaaS) instant issuance, today announced a referral relationship with MEA Financial Enterprises LLC (“MEA”), a national leader in the provision of innovative software solutions to the financial services marketplace.
  • This is expected to expand CPI’s client base and enhance the services that MEA provides to its mobile app users – which include approximately 300 financial institutions.
  • “By partnering with CPI to offer Push Provisioning, our financial institutions can provide an instant solution to their customers’ needs.
  • The company offers digital solutions like UniFI Banking and supports mobile banking across all operating systems, in addition to providing phone support, a text concierge, and other software tools for financial institutions.

Expansa Completes Construction and Commissioning of a New Resin Regeneration Facility

Retrieved on: 
Wednesday, March 27, 2024
UF, CPI, Regeneration, DI, Water, Filtration, Food processing, NF, MMF, NGL, HPI, Portable, Municipality, Silviculture

HOUSTON, March 27, 2024 /PRNewswire/ -- Expansa, a privately held U.S. based industrial and municipal water treatment solutions provider, has completed construction and commissioning of its Resin Regeneration Plant adding much needed capacity to the "service deionization" market.

Key Points: 
  • HOUSTON, March 27, 2024 /PRNewswire/ -- Expansa, a privately held U.S. based industrial and municipal water treatment solutions provider, has completed construction and commissioning of its Resin Regeneration Plant adding much needed capacity to the "service deionization" market.
  • Key Elements of the Facility Include:
    Phase 1 of the project adds up to 288,000 cubic feet of resin regeneration capacity per year.
  • The Operations Team has completed the initial commissioning phase and will be ramping up production over the coming months.
  • "The opening of our resin regeneration plant marks a pivotal moment in our journey towards serving our customers' growing water purification needs.

Safer Schools, Better Behaviour Campaign: CPI's Essential Breaking Up Fights™ Training Offers Immediate Solution for Staff to Address Spike in Violence in School

Retrieved on: 
Tuesday, March 26, 2024
School, Intervention, CPI, Aggression, Risk, CPD, Student, Panic, Injury, Ambiguity, The central science, Training, Safety, Nursing

MANCHESTER, England, March 26, 2024 /PRNewswire/ -- Recent surveys from CPI (Crisis Prevention Institute)[1] and TeacherTapp[2] reveal that a third of teachers witness a fight among pupils on a weekly basis, a 55% increase in the last 2 years.  While 96% of teachers feel obligated to intervene, mindful of their duty of care toward pupils, yet 74% feel unclear on intervention guidance within school settings. This leaves teachers ill-prepared to address physical altercations among students.

Key Points: 
  • While 96% of teachers feel obligated to intervene, mindful of their duty of care toward pupils, yet 74% feel unclear on intervention guidance within school settings.
  • In response to this pressing need, CPI has launched a training solution tailored specifically for school staff.
  • Breaking Up Fights™: Intervention Skills training equips staff with essential strategies to maximise safety and minimise harm.
  • With a 97% satisfaction rate, Breaking Up Fights™ Training has already proven its effectiveness in addressing the critical challenges faced by school staff.